{
  "issued_date": "2013-04-02", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON257641", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL 13(A)11", 
    "Audience": "Healthcare professionals", 
    "Published": "2 April 2013", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "2", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 2 Drug Alert (Action Within 48 Hours): Miacalcic 200 IU Nasal Spray Solution - Novartis Pharmaceuticals UK Ltd - EL 13(A)11 (169Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con257644.pdf", 
      "filename": "downloads/2c46ae8d8bfb0b868d71b5790f511a9c9db25726/con257644.pdf", 
      "original_filename": "con257644.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 2 MEDICINES RECALL\n\nAction Within 48 Hours\n\n  \n\n\nPharmacy, Clinic and Wholesaler Level Recall  \n  \n02 April 2013  |   |  EL 13(A)11  |   |  Our ref:\u00a0 MDR 42-03/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nNovartis Pharmaceuticals UK Ltd\n\nMiacalcic 200 IU Nasal Spray Solution\n\nCalcitonin (salmon)\n\nPL 00101/0586\n\nAll unexpired stock of this product is being recalled to pharmacy, clinic and wholesaler level irrespective of batch number and expiry date.\n\nThe product is being withdrawn throughout the European Union after a study has shown an increased risk of malignancies with the long term use of calcitonin. Both the Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee have concluded that the benefits no longer outweigh the risks.\n\nNo further Miacalcic 200 IU Nasal Spray Solution should be dispensed. Pharmacists should refer patients with new or repeat prescriptions to the treating physician to review their treatment plan on a non-urgent basis.\n\nRemaining stocks of the affected batches should be quarantined and returned to the original supplier for credit. \u00a0For enquiries relating to stock returns please contact Novartis Pharmaceuticals Customer Care team on 08457-419442 or email [novartis.customercare@novartis.com](mailto:%20novartis.customercare@novartis.com).\n\nFor medical information enquiries please contact Novartis Pharmaceuticals UK Ltd Medical Information on 01276 698370 or email [medinfo.uk@novartis.com](mailto:%20medinfo.uk@novartis.com).\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.\n\nYours faithfully  \n  \nAdam Burgess  \nMHRA DMRC Manager\n\nMHRA Distribution (further recipients by cascade):  Regional Contacts for NHS Trusts and provider units  \nChief Pharmacists: England, Scotland, Wales, Northern Ireland  \nPrison Health Policy Unit (DH)  \nChief Pharmacists: \u00a0Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar  \nSpecial Hospitals  \nHealthcare Commission for distribution to independent health care establishments  \nPrimary care trusts (England) \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 2 MEDICINES RECALL</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Action Within 48 Hours</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Pharmacy, Clinic and Wholesaler Level Recall</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t02 April 2013\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL 13(A)11\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 42-03/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Novartis Pharmaceuticals UK Ltd</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Miacalcic 200 IU Nasal Spray Solution</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Calcitonin (salmon)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>PL 00101/0586</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON257641 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p></p><p>All unexpired stock of this product is being recalled to pharmacy, clinic and wholesaler level irrespective of batch number and expiry date.</p>\n\n<p>The product is being withdrawn throughout the European Union after a study has shown an increased risk of malignancies with the long term use of calcitonin. Both the Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee have concluded that the benefits no longer outweigh the risks.</p>\n\n<p>No further Miacalcic 200 IU Nasal Spray Solution should be dispensed. Pharmacists should refer patients with new or repeat prescriptions to the treating physician to review their treatment plan on a non-urgent basis.</p>\n\n<p>Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit. &#160;For enquiries relating to stock returns please contact Novartis Pharmaceuticals Customer Care team on 08457-419442 or email <a href=\"mailto:%20novartis.customercare@novartis.com\">novartis.customercare@novartis.com</a>.</p>\n\n<p>For medical information enquiries please contact Novartis Pharmaceuticals UK Ltd Medical Information on 01276 698370 or email <a href=\"mailto:%20medinfo.uk@novartis.com\">medinfo.uk@novartis.com</a>.</p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.</p>\n\n<p>Yours faithfully<br>\n<br>\nAdam Burgess<br>\nMHRA DMRC Manager</p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tRegional Contacts for NHS Trusts and provider units<br>\nChief Pharmacists: England, Scotland, Wales, Northern Ireland<br>\nPrison Health Policy Unit (DH)<br>\nChief Pharmacists: &#160;Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar<br>\nSpecial Hospitals<br>\nHealthcare Commission for distribution to independent health care establishments<br>\nPrimary care trusts (England)\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON257641 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON257641/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON257644` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 2 Drug Alert (Action Within 48 Hours): Miacalcic 200 IU Nasal Spray Solution - Novartis Pharmaceuticals UK Ltd - EL 13(A)11", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}